Using advanced imaging to evaluate Kaposi sarcoma
Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial
This study is testing if a special 3D camera can help doctors get better images of Kaposi sarcoma skin lesions in patients to track how well treatments are working.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT06751355 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the feasibility of using a SkinScan3D camera to capture detailed 3D images of Kaposi sarcoma lesions. The study focuses on patients diagnosed with Kaposi sarcoma who have multiple skin lesions, as traditional 2D imaging may not adequately represent the complexity of these tumors. By obtaining accurate 3D imaging, the study seeks to improve the evaluation of treatment responses and disease progression in patients with this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with histologically or cytologically proven Kaposi sarcoma and have at least three cutaneous lesions.
Not a fit: Patients without a diagnosis of Kaposi sarcoma or those with fewer than three lesions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate assessments of Kaposi sarcoma lesions, improving treatment monitoring and outcomes for patients.
How similar studies have performed: While the use of advanced imaging techniques in oncology is growing, this specific approach to evaluating Kaposi sarcoma lesions using 3D imaging is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria: * Have been diagnosed with histologically or cytologically proven Kaposi sarcoma (KS). * Patients may be off treatment or on treatment for their KS. * Has at least 3 cutaneous Kaposi sarcoma lesions. * At least 18 years of age. * Ability to understand and willingness to sign an IRB approved written informed consent document.
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Lee Ratner, M.D., Ph.D. — Washington University School of Medicine
- Study coordinator: Lee Ratner, M.D., Ph.D.
- Email: lratner@wustl.edu
- Phone: 314-362-8836
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.